Introduction
Changes in immune system parameters have been frequently observed in epileptic patients undergoing long-term anticonvulsant therapy [1, 2] . Although the contribution of anticonvulsant drugs to these changes is still uncertain, phenytoin (PHT) has been considered responsible for some specific immune alterations [3] . PHT has been utilized as an anticonvulsant agent since the late 1930s [4] .
A correlation between chronic PHT administration and IgA reduction has been well documented [5] . SORRELL et al. [6] were first to report abnormally low concentrations of serum IgA in some patients receiving long-term PHT therapy. Since this initial report in 1971 , several authors [7, 8] have noted an association between PHT therapy and depression of serum IgA concentration. Such IgA depression has been reported in 12-70% of patients treated with PHT191 . The treated patients with low IgA had a normal number of lymphocytes with surface IgA , suggesting that PHT causes failure of terminal differentiation of IgA-bearing B SMITH et al.
[111 studied the influence of PHT on IgA in both serum and total and parotid saliva. They noted that PHT induced a significant decrease in serum IgA levels and a significant increase in both salivary IgA levels and the rate of IgA secretion by the parotid gland .
The use of PHT has been frequently associated with side effects [12] . Some of the effects do not appear to be dose-related, and include problems such as gingival hyperplasia , hypertrichosis and leukopenia [9] . VAN dER KWAST [13] suggested in 1956 that the immune system was involved in PHT-induced gingival hyperplasia (PHT-IGH). It has since been suggested that IgA is a factor in PHT-IGH [14] [15] [16] . On the other hand, the influence of dental plaque on drug-induced gingival hyperplasia (DIGH) is well documented [17] [18] [19] [20] (Table 3) . A weak negative correlation was also found between the salivary IgA level and GOI (r=-0.13) (p>0.05) in the PHT-TEP group (Table 4) . Salivary IgA level showed a weak positive correlation with PD (r=0.16) (p>0.05) and also with PI (r= 0.33) (p>0.05) in the patient group (Table 4) . 2. There was no difference in salivary IgA levels between the PHT-TEP and control groups.
3. Weak negative correlations were found between serum IgA levels and GOI, and between salivary IgA levels and GOI.
